Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OCGN – Ocugen, Inc.

Ocugen, Inc.
OCGN
$1.06
Name : Ocugen, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $308,092,704.00
EPSttm : -0.2
finviz dynamic chart for OCGN
Ocugen, Inc.
$1.06
10.71%
$0.1021

Float Short %

24.27

Margin Of Safety %

Put/Call OI Ratio

0.07

EPS Next Q Diff

-0.01

EPS Last/This Y

-0.03

EPS This/Next Y

-0.01

Price

0.95

Target Price

6.5

Analyst Recom

1

Performance Q

51.11

Relative Volume

2.68

Beta

4.24

Ticker: OCGN




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07OCGN0.66150.070.1427787
2025-05-08OCGN0.6930.070.1727872
2025-05-09OCGN0.66960.080.0328647
2025-05-12OCGN0.69430.080.1428858
2025-05-13OCGN0.70250.080.0029080
2025-05-14OCGN0.70120.080.1629322
2025-05-15OCGN0.7090.080.0129518
2025-05-16OCGN0.75380.080.2130433
2025-05-19OCGN0.76940.080.0929380
2025-05-20OCGN0.81660.080.0129599
2025-05-21OCGN0.830.070.0231464
2025-05-22OCGN0.91280.070.0232453
2025-05-23OCGN0.92740.070.0733306
2025-05-27OCGN0.95790.070.0234340
2025-05-28OCGN0.87980.060.3035506
2025-05-29OCGN0.83420.070.0435841
2025-05-30OCGN0.83620.070.0535994
2025-06-02OCGN0.83780.070.1436104
2025-06-03OCGN0.85210.070.0136694
2025-06-04OCGN0.880.070.0136944
2025-06-05OCGN0.95290.070.1336763
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07OCGN0.66-20.0- -0.26
2025-05-08OCGN0.69-20.0- -0.26
2025-05-09OCGN0.67-20.0- -0.26
2025-05-12OCGN0.70-20.0- -0.26
2025-05-13OCGN0.70-20.0- -0.26
2025-05-14OCGN0.70-20.0- -0.26
2025-05-15OCGN0.71-20.0- -0.26
2025-05-16OCGN0.75-20.0- -0.23
2025-05-19OCGN0.77-41.7- -0.23
2025-05-20OCGN0.81-41.7- -0.23
2025-05-21OCGN0.82-41.7- -0.23
2025-05-22OCGN0.91-41.7- -0.23
2025-05-23OCGN0.93-41.7- -0.23
2025-05-27OCGN0.96-41.7- -0.23
2025-05-28OCGN0.88-41.7- -0.23
2025-05-29OCGN0.83-41.7- -0.23
2025-05-30OCGN0.84-41.7- -0.23
2025-06-02OCGN0.83-41.7- -0.23
2025-06-03OCGN0.85-41.7- -0.23
2025-06-04OCGN0.88-41.7- -0.23
2025-06-05OCGN0.95-41.7- -0.23
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07OCGN0.67-10.2823.95
2025-05-08OCGN0.67-10.2823.95
2025-05-09OCGN0.67-10.2823.95
2025-05-12OCGN0.67-12.5923.79
2025-05-13OCGN0.67-12.5923.79
2025-05-14OCGN0.67-12.5923.79
2025-05-15OCGN0.59-12.5923.85
2025-05-16OCGN0.59-12.5923.85
2025-05-19OCGN0.67-12.2723.79
2025-05-20OCGN0.67-12.2723.79
2025-05-21OCGN0.67-12.2723.79
2025-05-22OCGN0.67-12.2723.79
2025-05-23OCGN0.67-12.2723.79
2025-05-27OCGN0.196.1423.79
2025-05-28OCGN0.196.1424.27
2025-05-29OCGN0.196.1424.27
2025-05-30OCGN0.196.1424.27
2025-06-02OCGN0.197.2424.27
2025-06-03OCGN0.007.2424.27
2025-06-04OCGN0.007.2424.27
2025-06-05OCGN0.007.2424.27
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.05

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

Institutional Transactions

7.24

Beta

4.24

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

6

Growth Score

21

Sentiment Score

6

Actual DrawDown %

94.9

Max Drawdown 5-Year %

-97.7

Target Price

6.5

P/E

Forward P/E

PEG

P/S

61.57

P/B

17.49

P/Free Cash Flow

EPS

-0.19

Average EPS Est. Cur. Y​

-0.23

EPS Next Y. (Est.)

-0.25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1160.86

Relative Volume

2.68

Return on Equity vs Sector %

-385.2

Return on Equity vs Industry %

-367.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

Ocugen, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 95
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
stock quote shares OCGN – Ocugen, Inc. Stock Price stock today
news today OCGN – Ocugen, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCGN – Ocugen, Inc. yahoo finance google finance
stock history OCGN – Ocugen, Inc. invest stock market
stock prices OCGN premarket after hours
ticker OCGN fair value insiders trading